Barriers to the Use of Insulin Therapy and Potential Solutions: A Narrative Review of Perspectives from the Asia–Pacific Region
Year: 2024
Type: review
Abstract: The rising prevalence of type 2 diabetes (T2D) is posing major challenges for the healthcare systems of many countries, particularly in the Asia-Pacific Region, in which T2D can present at younger ages and lower body mass index when compared with Western nations. There is an important role for insulin therapy in the management of T2D in these nations, but available evidence suggests that insulin is under-utilized and often delayed, to the detriment of patient prognosis. The authors of this article gathered as an advisory panel (representative of some of the larger Asia-Pacific nations) to identify their local barriers to insulin use in T2D, and to discuss ways in which to address these barriers, with their outputs summarized herein. Many of the key barriers identified are well-documented issues of global significance, including a lack of healthcare resources or of an integrated structure, insufficient patient education, and patient misconceptions about insulin therapy. Barriers identified as more innate to Asian countries included local inabilities of patients to afford or gain access to insulin therapy, a tendency for some patients to be more influenced by social media and local traditions than by the medical profession, and a willingness to switch care providers and seek alternative therapies. Strategies to address some of these barriers are provided, with hypothetical illustrative case histories.
Source: Diabetes Therapy
Institutions: UNSW Sydney, St Vincent's Hospital Sydney, Hayatabad Medical Complex, Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders, Mahidol University, Ramathibodi Hospital, University Malaya Medical Centre, University of Malaya, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Hospital, Iran University of Medical Sciences, Tehran University of Medical Sciences, Madras Diabetes Research Foundation, Dr. Mohan's Diabetes Specialities Centre, University of the Philippines Manila, University of Indonesia, Yeungnam University College, Yeungnam University, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,850
Funder: Novo Nordisk
OpenAlex ID: W4394850324
